NCT06643000
Evaluating High-dose Furmonertinib with Bevacizumab and Pemetrexed for EGFRm NSCLC with Leptomeningeal Metastasis
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
Notable Trial status: Not Yet Recruiting to Recruitingv2 Show 5 more changesShow less
- Study sites: 1 to 2
- Primary completion date: Jan 2025 to Mar 30, 2025
- Study completion date: Mar 2025 to May 30, 2025
- Start date changed from estimate of Oct 2024 to Dec 20, 2024
- Study description expanded, about 1 word
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
OS
Timeframe: the time between the date of enrollment and the date of death from any cause
Secondary (3)
TTF
ORR-LM
CRR
Arms and interventions
Triple therapyExperimental
furmonertinib combined with bevacizumab and pemetrexed
Drugs: furmonertinib
Sites
2 sites in 1 country